Litcius/Paper detail

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study

Tasuku Harada, Yutaka Osuga, Yusuke Suzuki, Masaki Fujisawa, Motoko Fukui, Jo Kitawaki

2021Fertility and Sterility52 citationsDOI

Topics & Concepts

LeuprorelinMedicineEndometriosisVisual analogue scalePelvic painAdverse effectTriptorelinRandomized controlled trialHormone antagonistClinical endpointGynecologyInternal medicineGonadotropin-releasing hormoneAntagonistAnesthesiaSurgeryLuteinizing hormoneHormoneReceptorEndometriosis Research and TreatmentMenopause: Health Impacts and TreatmentsUterine Myomas and Treatments
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study | Litcius